ENTA (Enanta Pharmaceuticals, Inc)
Insider Trading Activity
Every open-market purchase and sale reported by ENTA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-10 | Scott T. Rottinghaus | Chief Medical Officer | F | — | — |
| 2026-03-13 | Lesley Russell | Director | A | — | — |
| 2026-03-13 | BRUCE L A CARTER | Director | A | — | — |
| 2026-03-13 | Kristine Peterson | Director | A | — | — |
| 2026-03-13 | Terry Vance | Director | A | — | — |
| 2026-03-13 | MARK G FOLETTA | Director | A | — | — |
| 2026-03-13 | Yujiro S Hata | Director | A | — | — |
| 2026-02-13 | Scott T. Rottinghaus | Chief Medical Officer | MIXED | — | — |
| 2026-02-13 | Matthew Paul Kowalsky | Chief Legal Officer | MIXED | — | — |
| 2026-02-13 | Tara Lynn Kieffer | Chief Product Strategy Officer | MIXED | — | — |
| 2026-02-13 | Brendan Luu | Chief Business Officer | MIXED | — | — |
| 2026-02-13 | Jay R. Luly | President and CEO | MIXED | — | — |
| 2026-02-13 | Yat Sun Or | Chief Scientific Officer | MIXED | — | — |
| 2025-12-05 | Harry R. Trout III | See Remarks | Sell | — | — |
| 2025-12-05 | Yat Sun Or | Chief Scientific Officer | Sell | — | — |
| 2025-12-05 | Scott T. Rottinghaus | Chief Medical Officer | Sell | — | — |
| 2025-12-05 | Jay R. Luly | President and CEO | Sell | — | — |
| 2025-12-05 | Tara Lynn Kieffer | Chief Product Strategy Officer | Sell | — | — |
| 2025-12-05 | Brendan Luu | Chief Business Officer | Sell | — | — |
| 2025-12-05 | Kathleen S. Capps | See Remarks | Sell | — | — |
| 2025-12-03 | Harry R. Trout III | See Remarks | MIXED | — | — |
| 2025-12-03 | Yat Sun Or | Chief Scientific Officer | F | — | — |
| 2025-12-03 | Brendan Luu | Chief Business Officer | F | — | — |
| 2025-12-03 | Jay R. Luly | President and CEO | F | — | — |
| 2025-12-03 | Tara Lynn Kieffer | Chief Product Strategy Officer | F | — | — |
| 2025-12-03 | Kathleen S. Capps | See Remarks | MIXED | — | — |
| 2025-11-26 | Scott T. Rottinghaus | Chief Medical Officer | A | — | — |
| 2025-11-26 | Matthew Paul Kowalsky | Chief Legal Officer | A | — | — |
| 2025-11-26 | Jay R. Luly | President and CEO | A | — | — |
| 2025-11-26 | Brendan Luu | Chief Business Officer | A | — | — |
| 2025-11-26 | Tara Lynn Kieffer | Chief Product Strategy Officer | A | — | — |
| 2025-11-26 | Yat Sun Or | Chief Scientific Officer | A | — | — |
| 2025-11-26 | Kathleen S. Capps | See Remarks | A | — | — |
| 2025-11-26 | Harry R. Trout III | See Remarks | A | — | — |
| 2025-08-08 | Scott T. Rottinghaus | Chief Medical Officer | F | — | — |
| 2025-03-14 | Kristine Peterson | Director | A | — | — |
| 2025-03-14 | BRUCE L A CARTER | Director | A | — | — |
| 2025-03-14 | Terry Vance | Director | A | — | — |
| 2025-03-14 | Lesley Russell | Director | A | — | — |
| 2025-03-14 | MARK G FOLETTA | Director | A | — | — |
| 2025-03-14 | Yujiro S Hata | Director | A | — | — |
| 2025-02-14 | Yat Sun Or | Chief Scientific Officer | MIXED | — | — |
| 2025-02-14 | Tara Lynn Kieffer | Chief Product Strategy Officer | MIXED | — | — |
| 2025-02-14 | Brendan Luu | Chief Business Officer | MIXED | — | — |
| 2025-02-14 | PAUL J MELLETT | Chief Fin. & Admin Officer | MIXED | — | — |
| 2025-02-14 | Jay R. Luly | President and CEO | MIXED | — | — |
| 2025-02-14 | Scott T. Rottinghaus | Chief Medical Officer | MIXED | — | — |
| 2025-02-12 | Jay R. Luly | President and CEO | Buy | — | — |
| 2024-12-10 | Jay R. Luly | President and CEO | Sell | — | — |
| 2024-12-10 | Scott T. Rottinghaus | Chief Medical Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 1,599,760 | — |
| — | 10%+ Owner | 1,490,028 | — |
| — | 10%+ Owner | 1,480,238 | — |
| — | President and CEO | 862,826 | — |
| — | Director | 547,606 | — |
| — | 10%+ Owner | 459,064 | — |
| — | 10%+ Owner | 389,835 | — |
| — | Director | 388,617 | — |
| — | Chief Scientific Officer | 378,267 | — |
| — | 10%+ Owner | 361,320 | — |
| — | 10%+ Owner | 285,129 | — |
| — | 10%+ Owner | 236,065 | — |
| — | 10%+ Owner | 145,442 | — |
| — | Chief Legal Officer | 111,614 | — |
| — | Chief Fin. & Admin Officer | 95,884 | — |
| — | Sr. VP & Chief Medical Officer | 65,267 | — |
| — | Chief Business Officer | 39,904 | — |
| — | Chief Product Strategy Officer | 33,925 | — |
| — | Chief Medical Officer | 23,787 | — |
| — | 10%+ Owner | 17,315 | — |
| — | Director | 17,287 | — |
| — | See Remarks | 16,348 | — |
| — | Senior Vice President | 12,127 | — |
| — | See Remarks | 8,377 | — |
| — | Director | 5,800 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ENTA quote page; the site-wide leaderboard is on the insider transactions hub.